The recognition that therapeutic intervention for achondroplasia is most effective during periods of active skeletal growth has fundamentally altered clinical practice patterns and referral algorithms.1 Contemporary understanding of growth plate biology and pharmacologic mechanism of action supports earlier therapeutic consideration, particularly given that growth velocity is highest during infancy and early childhood.1 Longitudinal growth studies in untreated achondroplasia demonstrate progressive deviation from typical growth trajectories beginning in infancy.2
The extension of regulatory approval of vosoritide to infancy aligns with emerging evidence that early intervention produces sustained benefits across all pediatric age groups.3 Early-age trials, including infants under two years, demonstrate improved growth and favorable safety. Additionally, findings support the potential to address early complications such as impaired foramen magnum growth with early intervention.3
Early diagnosis is essential to enable timely therapeutic access during optimal growth periods. Prenatal diagnosis through ultrasound findings suggestive of skeletal dysplasia is not always available as findings are typically not visible until the third trimester, if at all.1 Expanded access to single-gene noninvasive prenatal testing (NIPT) may lead to earlier diagnosis and allow for counseling and planning before birth.1 Postnatal diagnosis relies on clinical features including relative macrocephaly, midface hypoplasia, rhizomelic limb shortening, and trident hand configuration, with molecular genetic testing confirming FGFR3 mutations. However, clinical findings may not be initially apparent in the newborn exam.1 As approximately 80% of achondroplasia cases are caused by de novo variants, index of suspicion may be low for biological pregnancies in average-height parents.1
It is important to recognize that while there are exciting new management options available for individuals with achondroplasia, not every child or family will choose to pursue growth-modulating treatment.1 Decisions regarding initiation must be grounded in shared decision making, with careful consideration of family values, expected benefits, treatment burden, and long-term goals. Multidisciplinary teams play a central role in supporting individualized care pathways, ensuring that families receive balanced information and ongoing comprehensive management regardless of whether pharmacologic therapy is elected.
Take our achondroplasia quiz to see how your knowledge compares to your peers.
